LFSC ETF (F/m Emerald Life Sciences Innovation ETF) is managed by Emerald ETF with $112.0M in net assets. LFSC expense ratio is 0.54%, holding 43 positions across sectors including Health Care, Unknown, Other. Inception date: 2024-10-30.

LFSC performance shows a YTD return of 14.63%. The 1-year return is 72.07%.

LFSC top holdings include Cogent Biosciences Inc (7.6%), Travere Therapeutics Inc (6.9%), Spyre Therapeutics Inc (5.9%), Kalvista Pharmaceuticals Inc (5.5%), Livanova Plc (5.3%). View all LFSC holdings, sector breakdown, or dividend history.

LFSC can be compared against other funds using the overlap calculator or side-by-side comparison tool. LFSC alternatives are available via the screener, along with tax-loss harvesting opportunities.